Sonex Health announced enrollment of the first patient in the Post-Market RegIStry of the Patient Experience when uSing UltraGuIdeCTR fOr Carpal TuNnel Release (MISSION) registry. Enrollment objectives target at least 2,000 patients at numerous investigational sites across the U.S.
MISSION is designed to be the largest multicenter clinical study in the United States assessing the treatment of patients suffering from carpal tunnel syndrome (CTS). This study will collect real-world, long-term data on patients with CTS who are treated with a carpal tunnel release (CTR) procedure using Sonex Health’s UltraGuideCTR using real-time ultrasound guidance (CTR-US).
MISSION investigators will determine whether a CTR procedure is indicated, and if so, the patients will be screened to determine eligibility for enrollment. If patients qualify and consent to participate in the MISSION registry, they will receive a CTR-US procedure, and then periodically provide post-procedure follow-up information over a period of two years.
UltraGuideCTR is a single-use, hand-held device indicated for the treatment of carpal tunnel syndrome. U.S. launch for trigger finger release occurred in 2022.
Sonex Health announced enrollment of the first patient in the Post-Market RegIStry of the Patient Experience when uSing UltraGuIdeCTR fOr Carpal TuNnel Release (MISSION) registry. Enrollment objectives target at least 2,000 patients at numerous investigational sites across the U.S.
MISSION is designed to be the largest multicenter clinical...
Sonex Health announced enrollment of the first patient in the Post-Market RegIStry of the Patient Experience when uSing UltraGuIdeCTR fOr Carpal TuNnel Release (MISSION) registry. Enrollment objectives target at least 2,000 patients at numerous investigational sites across the U.S.
MISSION is designed to be the largest multicenter clinical study in the United States assessing the treatment of patients suffering from carpal tunnel syndrome (CTS). This study will collect real-world, long-term data on patients with CTS who are treated with a carpal tunnel release (CTR) procedure using Sonex Health’s UltraGuideCTR using real-time ultrasound guidance (CTR-US).
MISSION investigators will determine whether a CTR procedure is indicated, and if so, the patients will be screened to determine eligibility for enrollment. If patients qualify and consent to participate in the MISSION registry, they will receive a CTR-US procedure, and then periodically provide post-procedure follow-up information over a period of two years.
UltraGuideCTR is a single-use, hand-held device indicated for the treatment of carpal tunnel syndrome. U.S. launch for trigger finger release occurred in 2022.
Copy to clipboard 
